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Survivin is a small protein that belongs to the inhibitor of apoptosis protein family. It is 
abundantly expressed in tumors compared to adult differentiated tissues, being associated 
with poor prognosis in many human neoplasms. This apoptotic inhibitor has a relevant role in 
both the promotion of cancer cell survival and in the inhibition of cell death. Consequently, 
aberrant survivin expression stimulates tumor progression and confers resistance to several 
therapeutic strategies in a variety of tumors. In fact, efficient survivin down-regulation or 
inhibition results in spontaneous apoptosis or sensitization to chemotherapy and radiotherapy. 
Therefore, all these features make survivin an attractive therapeutic target to treat cancer. 
Currently, there are several survivin inhibitors under clinical evaluation, although more specific 
and efficient survivin inhibitors are being developed. Moreover, novel combination regimens 
targeting survivin together with other therapeutic approaches are currently being designed 
and assessed. In this review, recent progress in the therapeutic options targeting survivin for 
cancer treatment is analyzed. Direct survivin inhibitors and their current development status 
are explored. Besides this, the major signalling pathways implicated in survivin regulation are 
described and different therapeutic approaches involving survivin indirect inhibition are 
evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as 
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1. Introduction 
Cancer is a heterogeneous group of diseases that results not just from aberrant cellular 
proliferation but also from lack of well-regulated cell death. Resistance to apoptosis is one 
important evasion mechanism by which tumor cells may present chemoresistance and thus 
contribute to cancer progression. Consequently, molecules involved in regulation of apoptosis 
are considered potential targets for cancer therapy. In this regard, survivin, the smallest 
member of the inhibitor of apoptosis protein (IAP) family, has recently emerged as an 
attractive drug target due to its dual role in cancer, both in cell cycle progression and apoptosis 
inhibition. In this review, the molecular mechanisms that regulate survivin gene expression 
and protein function are summarized, as well as specific survivin inhibitors and other 
therapeutic strategies involving survivin inhibition are discussed. 
1.1. IAPs function and structure 
The IAP family embraces a functionally and structurally related group of proteins that function 
as endogenous cellular inhibitors of apoptosis in response to daily stresses and insults. Due to 
its relevance as negative regulators of programed cell death, a dysregulation of IAPs is closely 
related to cancer development and drug resistance 1. 
Structure of all mammalian IAPs members contains one to three defining baculovirus IAP 
repeat (BIR) domains encoding a zinc-finger motif typically arranged at the N-terminus of the 
protein (Figure 1a). Although the BIR domain is shared by all members of the IAP family, not all 
BIR-containing proteins exhibit antiapoptotic functions 2. This domain mediates protein 
recognition and protein-protein interactions 3. In addition to the BIR domain, several IAP family 
members contain a zinc-finger domain called RING (really interesting new gene), which 
functions as an E3 ubiquitin ligase, an ubiquitin-associated (UBA) domain, a ubiquitin-
conjugating (UBC) domain, and/or a caspase-recruitment domain (CARD). 
Among all the IAPs, survivin is the smallest member of the IAP family. Encoded by BIRC5 gene 
(baculoviral inhibitor of apoptosis repeat-containing 5), mapped to chromosome 17q25, 
survivin is a 16.5 kDa protein that contains only a single N-terminus BIR domain linked to a C-
terminal α-helical coiled coil domain. The latter domain is important for the interaction and 
formation of the chromosomal passenger complex (CPC), proper segregation of chromosomes 
and cytokinesis during cell division 4,5. A dimerization domain at two different locations in the 
linear sequence of survivin allows it to form a stable homodimer that seems to carry out its 
mitotic activity, while the monomeric form of survivin is mostly associated with its 
antiapoptotic activity 6,7 (Figure 1b and 1c). Moreover, different functions of survivin seem to 
be affected by differential subcellular localization, being the nuclear survivin related to cell 
division regulation while cytosolic survivin is believed to function as apoptotic suppressor 
(Figure 2) 8. Additionally, a small pool of survivin can be found in the mitochondria, from where 
is rapidly released to the cytosol in response to cell death stimulation and confers resistance to 
apoptosis 9. 
Although the overexpression of survivin inhibits both extrinsic and intrinsic apoptosis 
pathways contributing to cancer progression, the exact molecular mechanism remains 
unknown. It has been reported a direct binding of survivin to effector caspases, but a 
prevailing model is that survivin inhibits apoptosis by interacting with other proteins (Figure 2). 
One of these interactions is a complex formation between survivin and X-linked inhibitor of 
apoptosis protein (XIAP) 10. This IAP-IAP complex enhances XIAP stability against ubiquitin-
dependent degradation, increasing in this way the ability of XIAP for inhibiting caspases 11. 
Another mechanism proposed is the formation of the complex between survivin and hepatitis 
B X-interacting protein (HBXIP), which binds to procaspase 9 preventing its recruitment to the 
apoptosome and later activation 12. 
1.2. Survivin as a promising therapeutic target 
Due to its dual role both in cell cycle promotion and apoptosis inhibition, survivin has been 
considered an ideal target for anticancer therapy. Indeed, several molecular approaches that 
block survivin expression and/or function are emerging as promising therapeutic strategies in 
cancer 13. Remarkably, survivin is almost undetectable in most normal differentiated tissues, 
but prominently expressed in most cancer malignancies 14. This expression pattern provides 
selectivity over the tumor cells, thus decreasing the potential side effects in treated patients. 
Moreover, survivin overexpression has already been correlated with tumor prognosis, being 
considered a biomarker with a negative correlation on patient clinical outcome and drug 
resistance in many cancers 15. Altogether, survivin overexpression in tumors and its key 
biological roles promoting carcinogenesis and chemoresistance, makes survivin a promising 
therapeutic target. 
 
2. Pharmacological options targeting survivin 
Since survivin has emerged as an ideal target for cancer drug discovery, many survivin 
inhibitors have been reported in the literature. Some of them are specific direct inhibitors 
(Figure 2, table 1) but others do not directly bind and interact with survivin protein itself, 
instead, they usually target other biomolecules and ultimately reduce survivin expression 
(Figure 3, table 2). In the following sections, we discuss the available information about 
survivin inhibitors developed so far, as well as the direct or indirect mechanisms by which they 
repress survivin. 
 
2.1. Survivin direct inhibitors: targeting survivin gene or protein 
2.1.1. Transcriptional inhibition of survivin 
The inhibition of survivin gene expression is a therapeutic strategy under clinical development 
with the final aim of counteracting the overexpression of survivin in tumor cells. For this 
purpose, several small-molecules inhibiting the survivin gene promoter or mRNA have been 
studied. 
YM155 was the first identified small-molecule inhibitor that targets and suppresses 
specifically the activity of the survivin promoter, regardless of p53 status 16. Interestingly, it 
suppressed survivin gene promoter and induced apoptosis in prostate cells as well as 
promoted tumor regression in human prostate PC3 ectopic xenograft tumors 16. Other 
preclinical studies showed the promising anti-cancer properties of YM155 against a panel of 
119 human cancer cell lines with an average inhibitory concentration (IC50) of 15 nM. 
Moreover, continuous 3- or 7-day YM155 infusion (1-10 mg/kg) in xenograft model 
demonstrated significant antitumor activity without significant toxicity, measured through 
bodyweight loss 17. Phase I study reported YM155 as a well-tolerated anticancer drug that 
showed some efficacy against blood cancers 18. However, in phase II studies, YM155 showed 
modest single-agent activity against non-small cell lung carcinoma (NSCLC), but with a disease 
control rate similar to another second-line agents for advanced NSCLC 19. The combination of 
YM155 with carboplatin and paclitaxel also exhibited a favorable safety profile but failed to 
demonstrate an improvement in response rate in advanced NSCLC 20.  
However, despite having evidence supporting that YM155 can antagonize survivin expression, 
recent data support that YM155 is a DNA damaging agent where suppression of survivin is a 
secondary event, probably a consequence of transcriptional repression21. Similarly, other 
study also suggests that inhibition of survivin occurs via suppression of EGFR signaling and its 
downstream factors 22. Therefore, YM155 may not be only considered a specific survivin 
inhibitor. 
On the other hand, a recent study identified other compound targeting survivin by high 
throughput screening of chemical libraries following in vitro and in vivo analysis 23. This 
compound, named FL118, is a nonselective small-molecule inhibitor of survivin expression 
that structurally resembles the topoisomerase I inhibitor, irinotecan. Its antitumor activity 
results from inhibiting survivin promoter activity and survivin gene expression. In addition, 
FL118 also downregulates the expression of myeloid cell leukemia 1 (Mcl-1) and some IAPs, 
such as XIAP and cellular inhibitor of apoptosis 2 (c-IAP2) 23. FL118 effectively inhibited cancer 
cell growth at concentrations lower of 1 nM in a p53 status-independent manner. The in vivo 
studies revealed that FL188 has greater antitumor efficacy without significant toxicity 
compared with leading first-line chemotherapeutics 23. 
In addition to small-molecules targeting survivin gene promoter, antisense oligonucleotides 
have also been developed to inhibit survivin expression. LY2181308 is one example of single-
strand antisense oligonucleotide that targets survivin by binding to and degrading its mRNA 
preventing its translation into protein and thus, limiting survivin expression. LY2181308 
showed significant reduction of both survivin mRNA and protein, as well as cell-cycle arrest, 
cell-death induction and tumor growth inhibition in several tumor cell lines and human tumor 
xenografts 24. Several clinical studies have been carried out showing a favorable safety profile 
but mixed clinical outcomes 25-27. As an example, while LY2181308 showed synergistic benefits 
in patients with refractory or relapsed acute myeloid leukemia when combined with 
cytarabine and idarubicin 26, no benefit was observed against solid tumors when LY2181308 
was used as a single agent or in combination with docetaxel/prednisone 27. 
SPC3042 (EZN-3042), another antisense oligonucleotide, was identified as a new agent with 
higher potency for survivin mRNA inhibition compared to former antisense agents, including 
LY2181308 28. However, SPC3042 not only targets survivin mRNA but also has significant effect 
over B-cell lymphoma 2 (Bcl-2) mRNA. Downregulation of survivin expression using SPC3042 
led to cell cycle arrest, pronounced cellular apoptosis and sensitization of prostate cancer cells 
to taxol treatment, both in vitro and in vivo. EZN-3042 showed, as a single agent, a 60% 
downmodulation of survivin mRNA in tumors of A549 and Calu-6 lung xenograft models and 
37-45% of tumor growth inhibition. In addition, when EZN-3042 was combined with paclitaxel, 
83% of tumor growth inhibition was achieved 29. Despite these promising outcomes, phase I 
trial of EZN-3042 was terminated due its dose-limiting toxicity 30. 
Finally, other gene therapy-based approaches are currently being studied, especially in 
combination with conventional chemotherapeutics. It has recently been demonstrated that 
small interfering (si) RNA against survivin, combined with temozolomide or etoposide, induced 
a synergistic cytotoxic effect in glioblastoma cells31. Moreover, the combination of the micro 
RNA miR-542-3p mimic in combination with paclitaxel significantly inhibited in vivo tumor 
growth of HER2-overexpressing breast cancer cells, overcoming their chemoresistance32. 
2.1.2. Protein-protein interaction abrogation 
2.1.2.1. Smac mimetics 
Second mitochondria-derived activator of caspase (SMAC/DIABLO) is a proapoptotic protein 
released from mitochondria upon apoptotic stimulation and promotes cytochrome c-
dependent apoptosis by binding to and antagonizing IAPs. In this sense, SMAC/DIABLO binds 
to XIAP releasing caspase-9 from the complex, leading to apoptosis activation. On the other 
hand, cytosolic survivin is able to bind to SMAC/DIABLO, through its AVPI peptide binding 
region, inhibiting its pro-apoptotic functions 33. Furthermore, survivin overexpression can also 
diminish the pro-apoptotic functions of SMAC/DIABLO by delaying its release from 
mitochondria through direct union after apoptotic stimuli 34. 
Withanone, a natural product derived from roots of Withania somnifera, was studied as a 
possible competitor of SMAC/DIABLO for its binding site in survivin protein. Computational 
docking analysis showed that withanone binds to survivin BIR domain in the same hydrophobic 
cavity as that of SMAC/DIABLO, therefore being able to interfere with its inhibitory activity 
against caspases 35. Although the anticancer properties of withanone have already been 
studied in several cancer cell lines 36, experimental analysis are needed to confirm whether this 
compound specifically binds and inhibits survivin. Similarly, analogs of the phenolic component 
of black pepper piperine have also been described as potential survivin inhibitors by binding to 
the hydrophobic cavity of the BIR domain 37. Piperine was capable to inhibit cell growth and 
induce apoptosis in several types of cancer cells, such as human colon cancer cells 38, and 
suppressed tumor growth and metastasis in mice models, but more studies are needed to 
determine whether its anticancer potential is mediated through survivin inhibition. 
In a more recent work, using similarity-based virtual screening for the AVPI peptide in the 
survivin-SMAC crystal complex, UC-112 was identified as a potent and selective survivin 
inhibitor 39. UC-112 showed potent cell growth inhibition in human melanoma and prostate 
cancer cell lines, as well as antitumor activity in in vivo studies. Furthermore, survivin levels 
were strongly downregulated upon UC-112 treatment in vitro and in vivo. Based on the UC-112 
scaffold, new survivin inhibitors, being the most potent ones the 4g and 10f, were designed 
and synthesized 40,41. Compared to UC-112, its analog 4g showed an activity improvement of 
four folds in growth inhibition of cancer cell lines. Moreover, both compounds maintained the 
high selectivity for survivin showed by its parent compound UC-112. In vivo studies also 
showed an effective suppression of tumor growth and strong induction of cancer cell apoptosis 
in tumor tissues. 
All this data, along with the promising outcomes given by other IAP-specific SMAC mimetics 42, 
which are under evaluation in early clinical trials both as monotherapy or in rational 
combination therapies, encourage the study of compounds with this mechanism of action. 
2.1.2.2. Hsp90-survivin inhibitors 
Another well-studied protein interaction is the association between heat shock protein 90 
(Hsp90) and survivin. Hsp90 directly binds, through its N domain, to the BIR domain of survivin 
43. Besides this, it has been studied how the chaperone function of Hsp90 is required to 
preserve survivin stability in vivo and disruption of this complex by using Hps90 inhibitors 
triggers loss of survivin via proteasomal-dependent degradation. Blockage of survivin-Hsp90 
complex formation promoted apoptosis and mitotic defects in cultured cells. Hence, molecular 
antagonists of survivin-Hsp90 interaction may provide another rational approach to treat 
cancer. 
Shepherdine, a small peptidomimetic, was rationally designed for this purpose 44. Shepherdine 
makes extensive contact with the N domain of Hsp90, thus destabilizing survivin and inducing 
massive death of tumor cells by apoptotic and nonapoptotic mechanisms. Shepherdine not 
only affects survivin expression but also destabilized other Hsp90 client proteins, however, it 
has been proved its good selectivity, because it does not affect normal cells while maintaining 
excellent antitumor activity. Systemic administration of shepherdine in vivo efficiently 
inhibited human tumor growth in mice without showing significant toxicity 44. 
Based on shepherdine, a non-peptidic small molecule called AICAR (5-aminoimidazole-4-
carboxamide ribonucleotide) has been identified, through structure- and dynamics-based 
rational design, as a new Hsp90 inhibitor 45. AICAR showed the capability of directly binding to 
the N-terminal domain of Hsp90 and destabilize its clients proteins, including survivin. 
Experimental tests showed that AICAR exhibits antiproliferative and proapoptotic activity in 
melanoma, prostate and cervical cancer cell lines, while not affecting proliferation of normal 
human fibroblasts 45. 
2.1.2.3. Survivin homodimerization inhibitors 
It is known that monomeric and dimeric forms of survivin coexist, being the homodimeric form 
more related with the promotion of mitosis by enhancing tubulin stability 6. Thus, 
development of specific inhibitors targeting the dimerization site of survivin may be a feasible 
approach to treat cancer. This strategy becomes more attractive due to studies that showed 
how exposition of the hydrophobic interface of a dimeric protein often cause conformational 
changes, which leads to destabilization and degradation of the protein 46. Furthermore, 
homodimerization interface of survivin is not shared with other IAPs, therefore inhibitors of 
this site may increase their selectivity against survivin. 
Abbott 8 was identified using NMR and affinity-based screening as a small soluble compound 
that binds to the dimer interface of survivin 47. Several analogues were further developed 
reaching compounds with nanomolar affinities, however, more studies are needed to evaluate 
their anticancer activity. 
In this context, using in silico screening targeting the critical dimerization core residues of 
survivin, LQZ-7 was identified 48. LQZ-7 was able to dissociate the dimeric survivin into 
monomers in vitro and to promote its proteasome-dependent degradation in cells. Further 
analysis of LQZ-7 analogs led to the identification of LQZ-7F, a compound able to disrupt more 
effectively survivin dimerization, cause proteasome-dependent degradation, mitotic arrest and 
inhibit cancer cell survival through induction of spontaneous apoptosis. LQZ-7F was also 
effective in suppressing PC3 xenograft tumor growth and reducing survivin levels, without 
showing significant toxicity in mice after multiple dosing48. 
2.1.2.4. Mitosis-related proteins inhibitors 
Survivin plays an essential role in cell mitosis, including chromosome segregation and 
cytokinesis, mostly as an integral component of CPC 49. It is well documented how depletion of 
survivin causes cell proliferation arrest, sustained prometaphase blockade, chromosomal 
defects and cytokinesis failure 50. Additionally, a distinct pool of subcellular survivin is 
associated with polymerized microtubules, sustaining their stability, thereby contributing to 
the bipolar spindle assembly 50. 
In this context and using in silico analysis, several hotspot residues related to protein-protein 
interaction were found in survivin, including its CPC complex interface 51. Therefore, a 
pharmacophore model was derived and used to virtually screen databases of compounds. 
Using this methodology, indinavir, a protease inhibitor approved for the treatment of human 
immunodeficiency virus (HIV), was identified as an inhibitor of the interaction of survivin with 
its binding partners, such as CPC complex. Indinavir was able to impart anti-proliferative and 
apoptotic activity in breast cancer cells, decreasing Aurora B and XIAP proteins and inducing 
caspase-3 activation. Although preliminary biochemical results indicate that indinavir could 
inhibit both survivin-Aurora B in the CPC, and survivin-XIAP interactions, further investigations 
are needed to understand the antiproliferative mechanism of action of this compound. 
In another in silico study, S12, a small molecule that targets a specific cavity adjacent to the 
survivin dimerization surfaces, was identified 52. S12 showed disruption of the spindle 
formation, which led to mitotic arrest of cancer cells, followed by cell death with no apparent 
toxic effect over non-proliferating and normal resting cells. Moreover, in vivo studies showed 
how S12 was able to inhibit tumor growth without producing systemic toxicity in animals 52. 
Finally, the importance of the protein complex formation between survivin and the small 
GTPase Ran (Ras-related nuclear protein) has also been studied. Ran is implicated in 
microtubule stability and mitotic spindle assembly in tumor cells 53. The small-molecule LLP-3, 
derived from Abbott 8 compound, showed an effective disruption of the survivin-Ran complex, 
leading to survival and growth inhibition of glioma stem cells, both in vitro and in vivo 54. 
2.2. Survivin indirect inhibitors: targeting key cellular signaling pathways  
It has already been shown that survivin expression, either through down or up-regulation, 
could be triggered by several signaling pathways. The most actively described are shown in 
Figure 3 and will be discussed below. 
2.2.1. Cell growth, proliferation and survival 
2.2.1.1. PI3K/AKT  
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or AKT) 
signaling pathway is involved in several cellular functions including cell proliferation, growth 
and survival. The tyrosine receptor activation, via external signals, leads to class I PI3K 
recruitment to the plasma membrane and consequent activation to unleash a cascade of 
phosphorylations that will result in AKT activation. The AKT pathway has abundant 
downstream components controlling several cellular processes and is inappropriately activated 
in many cancers. Constitutive activation of PI3K receptor and somatic mutations in any 
component of the pathway or its negative regulators were observed in many cancers 55. During 
normal angiogenesis, the activation of PI3K/AKT pathway through upstream stimulation of 
vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) 
or angiopoietin 1 (Ang1)/angiopoietin receptor (Tie2), leads to an increase in survivin 
expression. Besides this, insulin growth factor (IGF-1)/PI3K/Akt/mammalian target of 
rapamycin (mTOR) signaling elevates survivin levels in prostate cancer cells via rapid changes 
in mRNA translation56. Likewise, several receptors (e.g. Granulocyte-macrophage colony-
stimulating factor receptor(GM-CSFR), epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 and 3 (HER-2 and HER-3) upregulate survivin levels 
through this route in cancer 32,57. 
Particularly, PI3K/AKT signaling is a potent regulator of survivin expression through different 
mechanisms: 1) activation of mTOR/Ribosomal protein S6 kinase beta-1 (p70S6K) axis induces 
the translation of various oncogenic proteins such as hypoxia-inducible factor 1-alpha (HIF-1α), 
which in turn control cell survival related genes such as survivin (upregulation) 58; 2) Mouse 
double minute 2 homolog (MDM2) negatively regulates the tumor suppressor p53, which 
decreases survivin expression via direct binding to the promoter 59; 3) AKT negatively regulates 
the transcription factors forkhead box protein O1 (FOXO1) and O3a (FOXO3a) that physically 
associate with the survivin promoter, repressing its expression 60 and 4) Nuclear factor kappa B 
(NF-κB), which is regulated upstream by the AKT/inhibitor of NF-κB kinase (IKK) axis, is 
associated with the transcriptional upregulation of survivin 61,62. 
Accordingly, inhibiting this pathway has become an important strategy in cancer treatment. In 
breast cancer, herceptin and lapatinib (HER-2 inhibitors) and AG1478 (EGFR inhibitor) inhibit 
survivin expression 63-65. In ovarian cancer, similar results were observed with the EGFR 
inhibitors gefitinib and PD153035 66,67. However, most reports have studied the inhibition of 
PI3K through LY294002 and wortmannin in several types of cancer: breast, colon, liver, ovary, 
lung and in leukemia 60,65,67-72. Concerning the inhibition of AKT, MK-2206 strongly blocks 
survivin in glioma and colon cancer 73. Moreover, SH5 inhibitor significantly reduces survivin 
levels in lung cancer 68 and similar results were observed with AKT inhibitor X in prostate 
cancer 69. Likewise, mTOR inhibitors, more specifically rapamycin, firmly downregulate survivin 
in glioblastoma, multiple myeloma and prostate cancer 58,74. The induction of survivin was also 
inhibited by the NF-κB inhibitors, SN50 and BAY 11-7082 in endothelial cells 61,75. Additionally, 
downregulation of survivin was observed with panepoxydone in breast cancer, and this seems 
to be related with NF-кB inhibition 76. Cyclooxygenase-2 (COX-2) induces survivin expression 
through AKT activation in several cancers (e.g. glioblastoma, lymphoma, myeloma, breast, 
colon and prostate) and this action could be reversed through its inhibitors, celecoxib and 
etodolac 77. 
2.2.1.2. JAK/STAT  
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling 
pathway plays a critical role in cell proliferation, differentiation, migration, apoptosis and 
immunity 78. A wide range of cytokines, hormones and growth factors, and their respective 
receptors stimulate the JAK/STAT pathway 78. JAK activation results in the recruitment and 
activation of STAT proteins that will then translocate to the nucleus and induce the 
transcription of target genes, such as survivin 78. It is known that dysregulation of JAK/STAT 
pathway participates in cancer development and metastasis 78. 
Interleukin 6 (IL-6), induce STAT3 activation leading to an increase on survivin expression in 
breast cancer cells 79. In leukemia, the up-regulation of survivin involving the JAK/STAT 
signaling pathway is dependent on GM-CSF 80 and breakpoint cluster region protein (BCR)-
Abelson murine leukemia viral oncogene homolog (ABL) 81. 
Interestingly, after blocking JAK2 kinase with the TG101209 inhibitor, a decrease of survivin is 
observed in leukemia 81. Another JAK2 inhibitor known as AG490 82 has shown to downregulate 
survivin in lymphoma as well as leukemia. Similar results were reported with the JAK2 inhibitor 
SD-1029 for breast and ovary cancers 83. Our group has also shown that novel indol-based 
tambjamine analogues were able to reduce survivin levels by inhibiting JAK/STAT pathway 
through an unknown mechanism of action 84 and unpublished data. 
2.2.1.3. MAPK/ERK  
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling 
mediates cellular proliferation, differentiation, survival, development, migration and 
apoptosis. Ligand binding to the tyrosine kinase receptor causes the dimerization and 
phosphorylation of its cytoplasmic domains. Adaptor proteins bind to the receptor, triggering 
Rat sarcoma (RAS) GTPase, which in turn activates a cascade of kinases: MAPKKK (Raf, rapid 
accelerated fibrosarcoma), MAPKK (MEK, mitogen-activated protein kinase kinase)) and MAPK 
(ERK). Activated ERK is transported to the nucleus where phosphorylates several transcription 
factors regulating several target genes including survivin. MAPK/ERK signaling is involved in 
cancer progression, particularly in proliferation and immune escape and numerous mutations 
have been identified in tumors, such as in RAS genes 55. 
Epidermal growth factor (EGF) induces the activation of MAPK/ERK signaling and increases 
survivin levels 85. Cytokines such as Granulocyte-macrophage colony-stimulating (GM-CSF) and 
the BCR-ABL tyrosine kinase could induce survivin expression via MAPK/ERK dependent 
mechanism in leukemia 86. Moreover, HER-2 up-regulation of survivin is regulated by 
MAPK/ERK signaling, apart from the PI3K/AKT contribution in breast cancer 70. Similar results 
were observed with c-Harvey rat sarcoma viral oncogene homolog (c-H-RAS), where both 
MAPK/ERK and PI3K/AKT are participating in survivin overexpression 72. 
Interestingly, MEK inhibitors significantly reduce survivin levels. In particular, PD98059 in 
breast cancer 65 and leukemia, and similar results were described with CI1040 in leukemia 86. 
Besides this, PD0325901 (a CI1040 derivative) prevented the placental lactogen induction of 
survivin 66. The U0126 inhibitor strongly blocks MAPK induction of survivin in leukemia 86, 
breast cancer 70 and keratinocytes 72. In addition, BCR-ABL inhibition by imatinib significantly 
hampers MAPK/ERK survivin expression in leukemia cells 86. 
2.2.2. Cell cycle regulation 
Survivin is expressed in a cell cycle-dependent way and localizes in the mitotic apparatus. The 
cyclin-dependent kinases (CDKs) 2/4 are active in both G1 and S phases and phosphorylate 
retinoblastoma (Rb) relieving it from the E2F transcription factors to allow the cell cycle 
transition. Survivin is positively regulated by E2F1, E2F2 and E2F3 through cell cycle-dependent 
element (CDE)/cell cycle genes homology region (CHR) dependent mechanism while is 
negatively regulated by E2F4 and E2F5 repressors 87. Moreover, the CDK1/cyclin-B1 pair 
phosphorylates survivin on Thr34, contributing to its stability and its association with caspases 
88. 
Some CDKs inhibitors, in addition to arresting the cell cycle, have an interesting ability to 
induce apoptosis. In addition, CDK inhibitors abrogate survivin phosphorylation on Thr34 
leading to its degradation 89. The specific CDKs inhibitor (purvalanol A) downregulates survivin 
through JAK/STAT inhibition in gastric cancer [79]. A broad spectrum CDK inhibitor known as 
flavopiridol inhibits survivin phosphorylation on Thr34, reducing its protein levels in cervical 
cancer and has shown its antitumor activity in several phase II clinical trials 90,91. The specific 
CDK2 inhibitor NU6140 also diminishes survivin expression in cervical and ovary cancers 88. 
Finally, Cephalochromin is a selective bacterial inhibitor that reduces the levels of CDK2/cyclin-
E and CDK4/cyclin-D1 pairs producing cell cycle arrest (G0/G1 phase) and consequently 
decreasing survivin expression and inducing apoptosis 92. 
2.2.3. Cellular stress: p38MAPK  
The p38MAPK signaling is involved in inflammation, cell cycle, cell death, development, 
differentiation and senescence 93. Environmental stresses (e.g. UV and heat) and inflammatory 
cytokines trigger this pathway by phosphorylation of MAPKKKs. These kinases signal the 
cascade through MKK3 and MKK6 and finally p38MAPK which will finally activate transcription 
factors (e.g. p53) that will regulate several target gene expression 93. 
Activation of the p38MAPK route by the COX-2 inhibitor celecoxib induces survivin 
downregulation in colon cancer cells 94. Likewise, oxaliplatin, a chemotherapeutic drug, leads 
to colon cancer cell death through survivin downregulation via p38MAPK pathway and via 
proteasomal degradation 95. 
2.2.4. Development and Differentiation 
2.2.4.1. TGFβ  
Transforming growth factor beta (TGF-β) signaling controls several cellular functions including 
cell growth, proliferation, differentiation, development and migration. Upon ligand binding, 
constitutively active TGF-β receptor II (TβRII) recruits and activates by phosphorylation the 
TβRI. Due to this activity, Smad proteins, Smad2 and Smad3, are phosphorylated and form a 
complex with co-Smad (Smad4) in the cytoplasm, which is then translocated to the nucleus 
where it regulates gene expression, including survivin 96. Although TGFβ is an important tumor 
suppressor, cancer cells subvert this pathway by taking control of the tumor promoting arm 96. 
Interestingly, an overexpression of TGF-β1 was described in various types of cancer. In 
addition, inactivating mutations on SMAD2 and SMAD4 were reported in hepatocellular, 
colorectal and lung cancer 96. 
The activation of the TGF-β pathway in colon cancer causes the hypophosphorylation of Rb via 
Smad3-dependent mechanism, which causes the association of Rb/E2F4 repressive complex to 
CDE/CHR elements of survivin gene promoting its downregulation 71,97. Similarly, TGF-β 
inhibition of PI3K/AKT signaling through protein kinase A (PKA)/A-kinase anchoring protein 
(AKAP149)/protein phosphatase 2 (PP2A) may also reduce the survivin levels 71,97. 
Furthermore, TGFβ activation of PKA, leads also to the phosphorylation of survivin in Ser20 
inducing its degradation 97. 
2.2.4.2. Wnt/β-Catenin  
Wnt signaling regulates stem cell pluripotency, differentiation and embryonic development. In 
absence of Wnt signaling, Adenomatous polyposis coli (APC)/Axin/glycogen synthase kinase 3 
beta (GSK-3β) inhibitory complex leads to the ubiquitination and degradation of β-catenin. 
Wnt receptors activation hampers this complex, displacing Axin and inhibiting GSK-3β activity. 
This leads to β-catenin accumulation in cytoplasm and its translocation to the nucleus where it 
binds to Lymphoid enhancer-binding factor (LEF)/TCF transcription factors and co-activators 
(e.g. CREB-binding protein, CBP) regulating a variety of genes, including survivin 98. 
A variety of Wnt and APC mutations and alterations are frequently observed in cancer 98. It has 
been reported that TCF/β-catenin induces survivin expression in lung, colorectal and breast 
cancers 63,98,99. 
Drugs binding to HER-2 receptor, such as Herceptin (trastuzumab) in breast cancer, 
compromise β-catenin stabilization and consequently decrease survivin expression 63. 
Furthermore, an antibody against Wnt2 protein, Wnt-2 Ab, induces apoptosis inhibiting this 
process in lung cancer 98. Downregulation of β-catenin and survivin expression by ICG-001 (a β-
catenin/CBP disruptor) was observed in colon cancer 100. 
2.2.4.3. Notch  
Notch signaling is involved in important cellular processes such as proliferation, development, 
differentiation and homeostasis 101. It mediates cell-cell communication through interaction 
with transmembrane ligands on adjacent cells. Ligand binding results in Notch receptor 
cleavage through γ-secretase releasing the notch intracellular domain (NICD) that is then 
translocated to the nucleus where it modifies DNA transcription. Particularly, NICD associates 
with CBF1/Su(H)/Lag1 (CSL) transcription factor in order to activate Notch target genes, 
including survivin 101,102. Hypoxia and Jagged-1 ligand activate Notch signaling increasing 
survivin expression in lung cancer 103. In addition, HIF-1α promotes Notch induction of survivin, 
suggesting that HIF1-α interacts with NICD facilitating the CSL transcription factor association 
with a RBP-Jĸ site in the survivin promoter 102. 
Aberrant Notch signaling has been associated with tumorigenesis and cancer progression in 
lung, pancreas and breast cancer models. In fact, mutations on Notch receptors and 
consequently nuclear overexpression of NICD were described in leukemia and lymphoma 101. 
Under hypoxia, both Echinomycin (HIF-1α inhibitor) and inhibitors of γ-secretase (MRK-003 
and a specific peptide inhibitor), decrease survivin expression in lung and breast cancers 102. 
2.2.5. Others  
Survivin promoter has several sites for the transcription factor Sp1 and mutations on some of 
those sites reduce survivin expression by 60-80% in cervical cancer 104,105. In contrast, Sp1 could 
also recruit transcriptional repressors such as p53, DNMT1 and HDAC and consequently 
suppress survivin promoter activity 106. Interestingly, Sp1 inhibition by mithramycin A or 
oxaliplatin significantly decreased survivin promoter activity in colon and esophageal cancers 
106,107. Moreover, the small molecule terameprocol significantly decreased survivin levels by 
hampering Sp1 binding to survivin promoter and through the downregulation of CDK1 that 
leads to survivin degradation. This effect was observed in colorectal, prostate, hepatic, 
erythroleukemia and breast cancers 108. 
Survivin has yet binding sites to other transcription factors as we have mentioned previously. 
Several of these transcription factors are important survivin inductors, like the GATA-1 109, c-
myc 110 and DEC1 111 transcription factors. KLF5 binds directly to survivin promoter on three 
specific sites inducing its expression, but could also interact with p53 and block its repression 
on survivin promoter 112. In addition, it has been reported that survivin is targeted by GLI2 
transcription factor, a Hedgehog signaling effector. Defective activation of hedgehog signaling 
has been described in many cancers. 11 GLI binding sites were found in survivin promoter. 
Inhibiting Hedgehog signaling through SMO inhibitor cyclopamine strongly reduces survivin 
promoter activity in melanoma 105. Besides, an specific inhibitor of GLI known as GANT61 also 
significantly inhibits survivin promoter activity and consequently reduces survivin protein in 
melanoma, colon, lung, pancreatic and adrenal gland cancers 105. Furthermore, palmatine has 
recently been described to inhibit GLI/collagen type 1 alpha 1 (COL1A1) in stellate cells and 
survivin in cancer cells 113. 
Other molecules have also shown to reduce survivin levels in several cancers: an inhibitor of 
CRM1 (KPT-185), a protein that plays a critical role in the nuclear export of proteins; SF002-96-
1 (natural lactone) through indirect inhibition of transcription factors, STAT3 and NF-кB 114 and 
several small molecules (e.g. GDP366, the HIV protease inhibitor Nelfinavir and the derivative 
of retinoic acid tretinoin) through an unknown mechanism of action 115-117. 
 
Concluding Remarks and future perspectives 
Many preclinical studies have extensively demonstrated that survivin has a relevant role in 
promoting tumor growth as well as inducing resistance to chemotherapy in several neoplasms. 
Moreover, survivin shows a differential expression, being preferentially and abundantly 
expressed in tumors but not in adult differentiated tissues. Altogether, these features make 
survivin a promising therapeutic target to treat cancer. However, early clinical data indicates 
that the first direct inhibitors of survivin available show modest activity as single agents and, in 
some cases, dose-limiting toxicities. These are the cases of LY2181308 oligonucleotide or the 
small-molecule inhibitor YM155. This limited response may be due to deficiencies in complete 
and selective survivin inhibition in patients and to tumor heterogeneity. Therefore, inhibitors 
with more specific mechanisms targeting survivin, such as smac mimetics or survivin 
homodimerization inhibitors, are expected to show better clinical results. On the other hand, 
several indirect survivin inhibitors are currently in clinical trials, such as flavopiridol or 
lapatinib, although their effects may be due to the combination of survivin inhibition together 
with other mechanisms of action 64,91. Additionally, efforts directed at identification of specific 
biomarkers useful for the selection of patients benefiting from the treatment should be made. 
Immunotherapy is another therapeutic approach under current evaluation. It is focused on 
targeting survivin through the stimulation of the immune system to provoke a direct response 
against the tumor. Some clinical trials, like vaccination with survivin-2B80-88 peptide 118, have 
shown limited clinical responses. On the other hand, the good tolerability demonstrated offer 
promise to optimize this therapeutic approach. Indeed, there is some expectation in several 
phase I and II clinical trials using survivin vaccines (NCT03029403, NCT03349450, among 
others), which are currently recruiting patients to evaluate its safety, tolerability and 
effectiveness in combination with other treatments. 
Finally, it is anticipated that the maximum therapeutic effect of survivin inhibitors will be 
completely achieved in combination regimens. Since targeting survivin sensitizes cancer cells 
to apoptosis 119, it is expected that survivin inhibitors will enhance the apoptotic effect induced 
by traditional chemotherapeutic drugs or radiotherapy, showing synergistic effects and 
overcoming the treatment resistance observed in some patients. Several studies combining 
chemotherapeutics with chemical survivin inhibitors have already demonstrated this ability 
86,91 and some others are currently under evaluation. This is also the case for novel gene 
therapy-based approaches targeting survivin, when administered in combination with 
chemotherapeutics. Preliminary studies have demonstrated that these combinations are able 
to enhance cancer cells sensitivity to chemotherapeutics 31 and overcome chemoresistance in 
certain types of cancers 32. 
The reviewed results underscore survivin as an attractive and promising cancer drug target. 
Future efforts may be focused on the development of synergistic combinations between direct 
or indirect survivin inhibitors, or gene therapy-based approaches, together with 
chemotherapeutic drugs in order to efficiently treat cancer. 
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Table 1. Direct survivin inhibitors. 
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Table 2. Indirect survivin inhibitors. 
Biological 
Process 





1 Herceptin HER-2 63 
2 Lapatinib HER-2 64 
3 AG1478 EGFR 65 
4 Gefitinib EGFR 66 
5 PD153035 EGFR 67 
6 LY294002 PI3K 
57,60,64,65,67-
72,75 
7 Wortmannin PI3K 68,72 
8 MKK-2206 AKT 73 
9 SH5 AKT 68 
10 AKT inhibitor X AKT 69 
11 Rapamycin mTOR 57,58,74 
12 SN50 NFкB 75 
13 BAY 11-7082 NFкB 61 
14 Panepoxydone NFкB 76 
15 Celecoxib COX-2 77 
16 Etodolac COX-2 77 
JAK/STAT 
17 TG101209 JAK2 81 
18 AG490 JAK2 82 
19 SD-1029 JAK2 83 
MAPK/ERK 
20 PD98059 MEK 65 
21 Cl1040 MEK 86 
22 PD0325901 MEK 66 
23 U0126 MEK 70,72,85,86 




25 Purvalanol A CDK1/2/4 90,120 
26 Flavopiridol CDK1/2/4/6 90 
27 NU6140 CDK2 88 
28 Cephalochromin CDK2/4 92 
Cellular stress p38 pathway 
15 Celecoxib COX-2 77,94 






30 TGF-beta TGF-beta receptor 71,97 
Wnt/β-catenin 
31 Wnt-2 Ab Frizzled Receptors 98 
32 ICG-001 β-catenin/CBP 100 
Notch 





35 MRK-003 γ-secretase 102 




Figure 1. a. Primary structure of IAP proteins in mammals. The main domains are shown in 
different colors. b. Structure of survivin protein. c. Structure of dimeric survivin protein. 
Figure 2. Survivin sub-cellular functions and direct survivin inhibitors. The main mechanisms of 
action of direct survivin inhibitors are shown. 1- Transcriptional inhibitors decrease survivin 
expression levels; 2-Smac mimetics impede that survivin inhibit caspases; 3-Hsp90 inhibitors 
destabilize the Hsp90-survivin complex, inducing survivin degradation. 4- Homodimerization 
inhibitors disassemble survivin homodimer, increasing survivin degradation. 5- Mitotic 
inhibitors prevent CPC complex formation and survivin interaction with other mitosis-related 
proteins.  
Figure 3. Signaling pathways that regulate survivin expression and their corresponding indirect 
survivin inhibitors. Red numbers correspond to those inhibitors listed in table 2. 
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